NASDAQ: ADMAAdma Biologics Inc Stock
$19.98-1.22 (-5.75%)
Updated May 9, 2025
ADMA Price
$19.98
Fair Value Price
N/A
Market Cap
$4.77B
52 Week Low
$8.42
52 Week High
$25.67
P/E
22.7x
P/B
12.77x
P/S
10.27x
PEG
1.71x
Dividend Yield
N/A
Revenue
$459.38M
Earnings
$206.77M
Gross Margin
52.6%
Operating Margin
33.28%
Profit Margin
45%
Debt to Equity
0.37
Operating Cash Flow
$101M
Beta
1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADMA Overview
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADMA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ADMA
Ranked#96 of 458
Ranked#96 of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $1.72 | A | |
| $44.23 | A | |
| $8.00 | A |
Be the first to know about important ADMA news, forecast changes, insider trades & much more!
ADMA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADMA ($19.98) is trading above its intrinsic value of $8.78, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ADMA is good value based on its earnings relative to its share price (22.7x), compared to the US market average (24.91x)
P/E vs Market Valuation
ADMA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ADMA due diligence checks available for Premium users.
Valuation
ADMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
22.7x
Industry
-160.18x
Market
24.91x
ADMA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ADMA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ADMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.77x
Industry
4.11x
ADMA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADMA price to earnings growth (PEG)
For valuing profitable companies with growth potential
ADMA is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
ADMA's financial health
Profit margin
Revenue
$114.8M
Net Income
$26.9M
Profit Margin
23.4%
ADMA's Earnings (EBIT) of $152.90M... subscribe to Premium to read more.
Interest Coverage Financials
ADMA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$510.6M
Liabilities
$137.2M
Debt to equity
0.37
ADMA's short-term assets ($351.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADMA's short-term assets ($351.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADMA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.7M
Investing
-$4.7M
Financing
-$7.1M
ADMA's operating cash flow ($101.22M)... subscribe to Premium to read more.
Debt Coverage Financials
ADMA vs Biotech Stocks
Adma Biologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.